
Cullinan Therapeutics, Inc. (NASDAQ:CGEM – Free Report) – Equities research analysts at HC Wainwright boosted their FY2026 earnings estimates for Cullinan Therapeutics in a research note issued to investors on Monday, November 16th. HC Wainwright analyst R. Burns now expects that the company will post earnings of ($3.24) per share for the year, up from their prior forecast of ($3.45). HC Wainwright currently has a “Buy” rating and a $35.00 target price on the stock. The consensus estimate for Cullinan Therapeutics’ current full-year earnings is ($3.06) per share. HC Wainwright also issued estimates for Cullinan Therapeutics’ Q4 2026 earnings at ($0.79) EPS, Q1 2027 earnings at ($0.81) EPS, Q2 2027 earnings at ($0.84) EPS, Q3 2027 earnings at $1.49 EPS, Q4 2027 earnings at ($0.84) EPS and FY2027 earnings at $1.00 EPS.
Several other equities analysts have also recently issued reports on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Cullinan Therapeutics in a research report on Friday, October 2nd. Wall Street Zen cut Cullinan Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, October 24th. BTIG Research raised their price target on Cullinan Therapeutics from $40.00 to $41.00 and gave the company a “buy” rating in a report on Wednesday, October 28th. TD Cowen upgraded Cullinan Therapeutics to a “strong-buy” rating in a research note on Monday, August 24th. Finally, Wedbush upped their price objective on Cullinan Therapeutics from $42.00 to $44.00 and gave the stock an “outperform” rating in a report on Wednesday, November 11th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Cullinan Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $34.14.
Check Out Our Latest Analysis on CGEM
Cullinan Therapeutics Stock Down 2.4%
Shares of NASDAQ:CGEM opened at $9.27 on Wednesday. Cullinan Therapeutics has a 52 week low of $8.23 and a 52 week high of $23.19. The company has a 50-day moving average price of $15.37 and a 200 day moving average price of $15.77. The company has a market cap of $601.81 million, a P/E ratio of -3.02 and a beta of -0.03.
Cullinan Therapeutics (NASDAQ:CGEM – Get Free Report) last posted its quarterly earnings results on Tuesday, November 10th. The company reported ($0.74) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.84) by $0.10.
Insider Activity at Cullinan Therapeutics
In related news, insider Jennifer Michaelson sold 4,000 shares of the firm’s stock in a transaction dated Thursday, November 5th. The shares were sold at an average price of $12.36, for a total value of $49,440.00. Following the completion of the sale, the insider owned 158,649 shares in the company, valued at $1,960,901.64. This trade represents a 2.46% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 8.60% of the stock is owned by company insiders.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently added to or reduced their stakes in CGEM. Quarry LP raised its holdings in Cullinan Therapeutics by 94.6% during the third quarter. Quarry LP now owns 18,825 shares of the company’s stock worth $289,000 after purchasing an additional 9,153 shares during the last quarter. Aquatic Capital Management LLC purchased a new stake in Cullinan Therapeutics during the third quarter worth $417,000. Apis Capital Advisors LLC boosted its position in Cullinan Therapeutics by 140.0% during the third quarter. Apis Capital Advisors LLC now owns 192,000 shares of the company’s stock worth $2,947,000 after purchasing an additional 112,000 shares in the last quarter. HighVista Strategies LLC acquired a new stake in Cullinan Therapeutics in the third quarter valued at $2,669,000. Finally, Fisher Asset Management LLC grew its holdings in Cullinan Therapeutics by 2,125.0% in the third quarter. Fisher Asset Management LLC now owns 800,961 shares of the company’s stock valued at $12,295,000 after purchasing an additional 764,963 shares during the last quarter. 86.31% of the stock is currently owned by institutional investors and hedge funds.
Cullinan Therapeutics Company Profile
Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing treatments for cancer and autoimmune diseases. The company advances a pipeline of investigational medicines, including antibody-based therapies and T-cell engagers designed to direct immune responses against disease-related cells. Its programs include CLN-619, an antibody being studied for solid tumors; CLN-049, a T-cell engager targeting FLT3 for acute myeloid leukemia; and CLN-978, a CD19-targeting T-cell engager being developed for B-cell-mediated autoimmune diseases.
Recommended Stories
- Five stocks we like better than Cullinan Therapeutics
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Cullinan Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cullinan Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
